283 related articles for article (PubMed ID: 30342639)
1. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.
Wang PH
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):623-624. PubMed ID: 30342639
[No Abstract] [Full Text] [Related]
2. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study.
Machida H; Matsuo K; Enomoto T; Mikami M
J Gynecol Oncol; 2019 Nov; 30(6):e113. PubMed ID: 31576698
[No Abstract] [Full Text] [Related]
4. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Wood GE; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():64-73. PubMed ID: 34607745
[TBL] [Abstract][Full Text] [Related]
5. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
6. Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab.
Verleye L; Castanares-Zapatero D; Devos C; De Gendt C; Silversmit G; Van Damme N; Hulstaert F; Thiry N; Neyt M
Int J Gynecol Cancer; 2023 Apr; 33(4):543-548. PubMed ID: 36604121
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging.
Kumar L; Pramanik R; Kumar S; Bhatla N; Malik S
Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):790-801. PubMed ID: 25840650
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
[TBL] [Abstract][Full Text] [Related]
9. Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery.
Kumar A; Cliby WA
Clin Obstet Gynecol; 2020 Mar; 63(1):74-79. PubMed ID: 31725415
[TBL] [Abstract][Full Text] [Related]
10. Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery?
Al Mutairi N; Le T
J Obstet Gynaecol Can; 2019 Feb; 41(2):185-190. PubMed ID: 30316718
[TBL] [Abstract][Full Text] [Related]
11. [Ⅱ.Comparison between Upfront Primary Debulking Surgery and Interval Debulking Surgery Following Neoadjuvant Chemotherapy for Primary Treatment of Ovarian Cancer].
Onda T
Gan To Kagaku Ryoho; 2019 Feb; 46(2):236-239. PubMed ID: 30914525
[No Abstract] [Full Text] [Related]
12. Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis.
Godfroy M; Loaec C; Berton D; Guérin-Charbonnel C; Classe JM
Int J Gynecol Cancer; 2023 Jan; 33(1):94-101. PubMed ID: 36517074
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer.
Everett EN
Cancer Cytopathol; 2017 Oct; 125(10):743-744. PubMed ID: 28759154
[No Abstract] [Full Text] [Related]
14. Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer.
Paris I; Cianci S; Vizzielli G; Fagotti A; Ferrandina G; Gueli Alletti S; Costantini B; Cosentino F; Capoluongo E; Pasqualoni M; Scambia G
Int J Hyperthermia; 2018; 35(1):370-374. PubMed ID: 30300042
[TBL] [Abstract][Full Text] [Related]
15. [Progress in preoperative evaluation methods regarding cytoreduction in patients with advanced ovarian cancer].
Liu J; Zhang K
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):854-859. PubMed ID: 28845013
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction.
DU F; Li P; Chen J; Gong Z; Chi C; Hu B; Chu H
Neoplasma; 2017; 64(1):108-113. PubMed ID: 27881011
[TBL] [Abstract][Full Text] [Related]
17. Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review.
Xu T; Wang L; Jia Y; Jia Z; Li Z; Cui S; Cui M
J Ovarian Res; 2019 Nov; 12(1):108. PubMed ID: 31711529
[TBL] [Abstract][Full Text] [Related]
18. [Surgical therapy of ovarian cancer].
Chovanec J; Feranec R; Náležinská M; Cacek T
Rozhl Chir; 2017; 96(6):237-241. PubMed ID: 28931288
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
Fotopoulou C
Int J Gynecol Cancer; 2020 Nov; 30(11):1665-1666. PubMed ID: 33046572
[No Abstract] [Full Text] [Related]
20. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
Cascales Campos PA; González Gil A
Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
